Amitriptyline chemical structure
Find information on thousands of medical conditions and prescription drugs.

Elavil

Amitriptyline hydrochloride (sold as Elavil®, Tryptanol®, Endep®) is a tricyclic antidepressant drug. It is a white, odorless, crystalline compound which is freely soluble in water and usually dispensed in tablet form. The empirical formula of its hydrochloride salt is C20H23N·HCl. more...

Home
Diseases
Medicines
A
B
C
D
E
E-Base
Ecstasy (drug)
Edecrin
Edrophonium
Edrophonium chloride
Efavirenz
Effexor
Eflornithine
Elavil
Eldepryl
Elidel
Eligard
Elitek
Elixomin
Elixophyllin
Ellagic acid
Elmiron
Eloxatin
Elspar
Emtriva
Emylcamate
Enalapril
Enalaprilat
Enalaprilat
Endep
Enflurane
Enoxaparin sodium
Entacapone
Enulose
Epi-pen
Epinephrine
Epirubicin
Epitol
Epivir
Epogen
Eprosartan
Ergocalciferol
Ergoloid Mesylates
Ergotamine
Eryc
Eryped
Erythromycin
Esgic
Eskalith
Esmolol
Estazolam
Estazolam
Estrace
Estraderm
Estradiol
Estradiol
Estradiol valerate
Estring
Estrogel
Estrone
Estrostep
Ethacridine
Ethambutol
Ethchlorvynol
Ethosuximide
Ethotoin
Etiracetam
Etodolac
Etopophos
Etoposide
Etorphine
Evista
Exelon
Exemestane
Hexal Australia
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Mechanism of Action

Amitriptyline affects serotonin and noradrenaline reuptake almost equally.

Uses

Approved

Amitriptyline is approved for the treatment of endogenous depression and involutional melancholia (depression of late life, which is no longer seen as a disease in its own right), and reactive depression and for depression secondary to alcoholism and schizophrenia.

Unapproved/Off-Label/Investigational

Amitriptyline may be prescribed for other conditions such chronic pain, postherpetic neuralgia (persistent pain following a shingles attack), fibromyalgia, interstitial cystitis, or irritable bowel syndrome.

A randomized controlled trial published in June of 2005 found that amitriptyline was effective in functional dyspepsia refractory to famotidine and mosapride combination therapy.

Read more at Wikipedia.org


[List your site here Free!]


Stimulant response - Data - of FDA to ephedra products - Brief Article
From Reason, 5/1/03 by Jacob Sullum

At the end of February, the Food and Drug Administration (FDA) signaled that it may ban dietary supplements containing the herbal stimulant ephedra if it decides they pose "a significant or unreasonable risk of illness or injury." That phrase is open to interpretation, but the risk posed by ephedra seems quite modest when compared to the risks associated with widely used over the-counter and prescription drugs.

Although press reports commonly cite an estimate of "at least 100 deaths" linked to ephedra, a RAND Corporation study commissioned by the FDA found only two documented deaths that were investigated to rule out other causes. Even in those cases, the FDA concedes, the evidence is not conclusive.

With an estimated 12 million to 17 million Americans taking something like 3 billion doses of ephedra products a year, FDA Administrator Mark McClellan admits that "serious adverse events from ephedra appear to be infrequent."

That point is underlined by data from the federal government's Drug Abuse Warning Network. Selected DAWN numbers for 1999 (the most recent year for which nationwide totals are available) indicate that two deaths--or even too--over several years would not make ephedra stand out on a list of drugs mentioned by medical examiners.

COPYRIGHT 2003 Reason Foundation
COPYRIGHT 2003 Gale Group

Return to Elavil
Home Contact Resources Exchange Links ebay